Evidence map›Paper›PMID 40539341›Full record

ArticleCurrent HIV research2025

Genotypic Diversity and Pre-Treatment Resistance Characteristic Analysis Among Newly Diagnosed HIV-1-Positive MSM from 2020-2022 in Jiaxing City, China.

Xiaofei Zhang, Ganglin Ren, Zhijian Ge, Shencong Lv, Ping Li, Yin Song, Miaomiao Jia, Yamei Zhou, Yong Yan, Guoying Zhu

Abstract read
PubMed Publisher
In one paragraph

Article in Current HIV research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaofei ZhangJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, 314050, China.ORCID 0009-0008-5705-5885
Ganglin RenJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, 314050, China.
Zhijian GeJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, 314050, China.
Shencong LvJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, 314050, China.
Ping LiJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, 314050, China.
Yin SongJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, 314050, China.
Miaomiao JiaJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, 314050, China.
Yamei ZhouJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, 314050, China.
Yong YanJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, 314050, China.
Guoying ZhuJiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing, 314050, China.

Funding

Jiaxing Science and Technology Bureau 2024AY30002, 2024AD30124
6 · The paper itself

Abstract

backgroundSince the first recorded HIV-1 infection in 1998, Jiaxing City has seen increasing HIV infections among men who have sex with men (MSM), necessitating targeted research to understand HIV-1 subtypes and drug resistance patterns to improve prevention and treatment strategies.

objectivesThe study aimed to assess the variety of HIV-1 subtypes, the pre-treatment drug resistance (PDR) among MSM in Jiaxing, China, and transmission dynamics of drug-resistant strains. The findings may contribute to the development of targeted HIV prevention and control strategies for the MSM population.

methodsPlasma samples from all newly reported cases of HIV-1 transmitted through male-tomale sexual contact in Jiaxing City from 2020 to 2022 were retrospectively analyzed. Demographic and epidemiological data were collected. Partial pol gene regions were amplified, sequenced, and analyzed for drug resistance mutations (DRMs) using the Stanford HIV Drug Resistance Database. The Calibrated Population Resistance (CPR) program was utilised to identify Surveillance Drug Resistance Mutation (SDRM). A molecular transmission network was constructed to investigate the scale of transmitted drug resistance (TDR) strains.

resultsWe obtained a total of 298 eligible genetic sequences, revealing a diverse distribution of HIV-1 subtypes, with CRF07_BC, CRF01_AE, and CRF55_01B as the most prevalent. Pretreatment DRMs were detected in 91 cases (30.5%), yielding an overall PDR prevalence of 11.0%. Resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) was most frequent (5.4% each). TDR prevalence reached 7.0%, showing an increasing trend (2020-2022). The molecular network analysis indicated sporadic dissemination of drug-resistant cases rather than large-scale transmission chains.

conclusionThe convergence of high HIV-1 subtype diversity, elevated PDR prevalence, rising TDR rates, and sporadic resistant strain transmission within MSM networks necessitates the sustained resistance surveillance and precision public health interventions.

Indexed as

Anti-HIV AgentsDrug Resistance, ViralGenetic VariationGenotypeHIV-1HIV InfectionsHomosexuality, MaleAdultChinaHumansMaleMiddle AgedMutationRetrospective StudiesYoung AdultAnti-HIV Agentsdrug resistanceHIV-1molecular transmission networkMSMpre-treatment drug resistance (PDR)transmitted drug resistance (TDR).

Identifiers

PMID40539341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.